ArticleBMC neuroscience2013
Photobiomodulation preserves behaviour and midbrain dopaminergic cells from MPTP toxicity: evidence from two mouse strains.
Article in BMC neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07467850 (Dual Stimulation for Spinal Cord Injury), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dual Stimulation for Spinal Cord Injury
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Photobiomodulation for Parkinson's Disease in Animal Models: A Systematic Review.Biomolecules · 2020Pooled it
- Overcoming challenges of clinical cell therapies for Parkinson's disease with photobiomodulation.Interdisciplinary medicine · 2024Article
- Photobiomodulation for Neurodegenerative Diseases: A Scoping Review.International journal of molecular sciences · 2024Article
- Parkinson's Disease and Photobiomodulation: Potential for Treatment.Journal of personalized medicine · 2024Review
- Transcranial photobiomodulation for brain diseases: review of animal and human studies including mechanisms and emerging trends.Neurophotonics · 2024Review
- Remote photobiomodulation targeted at the abdomen or legs provides effective neuroprotection against parkinsonian MPTP insult.The European journal of neuroscience · 2023Article
- Transcranial near-infrared light in treatment of neurodegenerative diseases.Frontiers in pharmacology · 2022Review
- The effect of photobiomodulation on the brain during wakefulness and sleep.Frontiers in neuroscience · 2022Review
- Transcranial Near Infrared Light Stimulations Improve Cognition in Patients with Dementia.Aging and disease · 2021Article
- Current application and future directions of photobiomodulation in central nervous diseases.Neural regeneration research · 2021Review
- Kolaviron ameliorates behavioural deficit and injury to striatal dopaminergic terminals via modulation of oxidative burden, DJ-1 depletion and CD45RMetabolic brain disease · 2020Article
- Targeting Mitochondrial Impairment in Parkinson's Disease: Challenges and Opportunities.Frontiers in cell and developmental biology · 2020Review
- Photobiomodulation Mitigates Cerebrovascular Leakage Induced by the Parkinsonian Neurotoxin MPTP.Biomolecules · 2019Article
- Photobiomodulation as a treatment for neurodegenerative disorders: current and future trends.Biomedical engineering letters · 2019Review
- Short-term Effects of Transcranial Near-Infrared Photobiomodulation on Motor Performance in Healthy Human Subjects: An Experimental SingleBlind Randomized Clinical Trial.Journal of lasers in medical sciences · 2019Article
- Brain Photobiomodulation Therapy: a Narrative Review.Molecular neurobiology · 2018Review
- Neuroprotective Surgical Strategies in Parkinson's Disease: Role of Preclinical Data.International journal of molecular sciences · 2017Review
- Photobiomodulation-induced changes in a monkey model of Parkinson's disease: changes in tyrosine hydroxylase cells and GDNF expression in the striatum.Experimental brain research · 2017Article
- Photobiomodulation and the brain: a new paradigm.Journal of optics (2010) · 2017Article
- Near-infrared light (670 nm) reduces MPTP-induced parkinsonism within a broad therapeutic time window.Experimental brain research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe have shown previously that near-infrared light (NIr) treatment or photobiomodulation neuroprotects dopaminergic cells in substantia nigra pars compacta (SNc) from degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Balb/c albino mice, a well-known model for Parkinson's disease. The present study explores whether NIr treatment offers neuroprotection to these cells in C57BL/6 pigmented mice. In addition, we examine whether NIr influences behavioural activity in both strains after MPTP treatment. We tested for various locomotive parameters in an open-field test, namely velocity, high mobility and immobility.
resultsBalb/c (albino) and C57BL/6 (pigmented) mice received injections of MPTP (total of 50 mg/kg) or saline and NIr treatments (or not) over 48 hours. After each injection and/or NIr treatment, the locomotor activity of the mice was tested. After six days survival, brains were processed for TH (tyrosine hydroxylase) immunochemistry and the number of TH⁺ cells in the substantia nigra pars compacta (SNc) was estimated using stereology. Results showed higher numbers of TH⁺ cells in the MPTP-NIr groups of both strains, compared to the MPTP groups, with the protection greater in the Balb/c mice (30% vs 20%). The behavioural tests revealed strain differences also. For Balb/c mice, the MPTP-NIr group showed greater preservation of locomotor activity than the MPTP group. Behavioural preservation was less evident in the C57BL/6 strain however, with little effect of NIr being recorded in the MPTP-treated cases of this strain. Finally, there were differences between the two strains in terms of NIr penetration across the skin and fur. Our measurements indicated that NIr penetration was considerably less in the pigmented C57BL/6, compared to the albino Balb/c mice.
conclusionsIn summary, our results revealed the neuroprotective benefits of NIr treatment after parkinsonian insult at both cellular and behavioural levels and suggest that Balb/c strain, due to greater penetration of NIr through skin and fur, provides a clearer model of protection than the C57BL/6 strain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.